Workflow
GLORY HEALTH(02329)
icon
Search documents
国瑞健康(02329) - 2023 - 中期业绩
2023-08-31 13:08
香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責,對其準確 性或完整性亦不發表任何聲明,並明確表示,概不對因本公告全部或任何部份內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 Glory Health Industry Limited 國 瑞 健 康 產 業 有 限 公 司 (於開曼群島註冊成立的有限公司) 2329 (股份代號: ) 截 至 二 零 二 三 年 六 月 三 十 日 止 六 個 月 的 中 期 業 績 公 告 財務摘要 - 截至二零二三年六月三十日止六個月(「報告期」)已簽約銷售額為人民 幣2,087.4百萬元,相應的已簽約建築面積(「建築面積」)約為165,883平方 米; - 報告期的收入為人民幣1,456.87百萬元,其中來自物業開發的收入為人 民幣1,186.25百萬元; - 截至二零二三年六月三十日,土地儲備的總建築面積達到7,105,675平方 米; - 報告期的已簽約平均售價(「平均售價」)為每平方米人民幣27,875.3元; ...
国瑞健康(02329) - 2022 - 年度财报
2023-04-27 14:55
Financial Performance - The company's contracted sales amounted to RMB 4,532 million, a decrease of 63% compared to RMB 12,404 million in the previous year[7]. - Total revenue for the year was RMB 3,905 million, down 61% from RMB 9,898 million in 2021[7]. - The gross profit fell to RMB 114 million, representing a 91% decline from RMB 1,247 million[7]. - The net loss attributable to shareholders was RMB 913 million, a significant drop of 500% compared to a profit of RMB 228 million in the previous year[7]. - The total assets decreased by 6% to RMB 57,386 million from RMB 61,073 million[7]. - The group's revenue for the year ended December 31, 2022, was RMB 3,904.7 million, a decrease of 60.6% compared to RMB 9,898.4 million for the previous year[39]. - Revenue from property development amounted to RMB 3,340.4 million, down 63.6% year-on-year, primarily due to a reduction in the area of completed projects and sales[39]. - The total contracted sales in 2021 were RMB 12,404.3 million, indicating a significant decline in sales performance in 2022[31]. - The total comprehensive income decreased from RMB 328.4 million as of December 31, 2021, to a loss of RMB 995.3 million as of December 31, 2022, mainly due to foreign exchange fluctuations and reduced capitalized financing costs[50]. - Cash and restricted bank deposits decreased from approximately RMB 935.0 million as of December 31, 2021, to approximately RMB 377.3 million as of December 31, 2022[52]. - Net operating cash inflow decreased from RMB 4,345.3 million as of December 31, 2021, to RMB 606.3 million as of December 31, 2022[53]. Land and Development - As of December 31, 2022, the company's land reserve totaled 7.21 million square meters, with a focus on urban renewal projects[16]. - The total land reserve as of December 31, 2022, was 7,207,130 square meters, with 1,142,870 square meters completed, 2,106,464 square meters under development, and 3,957,795 square meters planned for future development[34]. - The group is actively engaged in first-level land development projects and urban renewal initiatives, particularly in cities like Beijing and Shenzhen[35]. - The group has ongoing urban renewal projects in Shenzhen, with a planned construction area of approximately 3 million square meters[38]. Strategic Focus and Future Plans - The company aims to transition towards the health industry, exploring innovative living concepts and developing health-related communities[19]. - The outlook for 2023 indicates a continued focus on stable and high-quality growth in the real estate sector, with an emphasis on regional development strategies[21]. - The group has a strategic focus on transforming into the health industry to explore broader market opportunities[23]. Financial Management and Costs - The sales and service costs for the year were RMB 3,791.2 million, a decrease of 56.2% compared to the previous year, mainly due to reduced area of completed projects[40]. - Distribution and selling expenses decreased by 63.5% from RMB 263.9 million as of December 31, 2021, to RMB 96.3 million as of December 31, 2022, due to reduced marketing costs resulting from decreased sales revenue[46]. - Administrative expenses decreased by 9.7% from RMB 403.6 million as of December 31, 2021, to RMB 364.3 million as of December 31, 2022, attributed to organizational restructuring and optimization[47]. - Financing costs increased by 95.1% from RMB 371.9 million as of December 31, 2021, to RMB 725.4 million as of December 31, 2022, primarily due to a reduction in capitalized financing costs[48]. Shareholder and Governance - The company does not recommend the payment of a final dividend for the year ended December 31, 2022[62]. - The company aims to enhance shareholder value through sustainable profit growth and stable dividend returns[91]. - The annual general meeting for shareholders is scheduled for June 28, 2023, with notifications to be published as per listing rules[97]. - The company recognizes the critical role of stakeholders, including employees and customers, in its success[85]. - The company has established a governance policy and regularly reviews compliance with legal and regulatory requirements[184]. Risk Management and Internal Control - The board is responsible for maintaining effective risk management and internal control systems to protect shareholder investments and company assets[200]. - The group has established a robust risk management and internal control framework involving the board, audit committee, internal control committee, and senior management[200]. - The board clarifies that the risk management system aims to manage, not eliminate, risks associated with achieving business objectives[200]. - Designated risk owners are responsible for developing risk mitigation plans to bring risks to acceptable levels[200]. - The internal audit department plays a crucial role in monitoring the company's internal governance[200]. Corporate Governance - The company has adopted the corporate governance code as per the listing rules and has complied with its provisions during the reporting period[161]. - The board consists of five executive directors and two independent non-executive directors as of December 31, 2022, with one independent non-executive director resigning on November 30, 2022[166]. - The board has established four committees, including the audit committee, remuneration committee, nomination committee, and internal control committee, to oversee specific aspects of the company's affairs[162]. - The company emphasizes the importance of transparency and accountability to shareholders and has implemented a board diversity policy[167]. Audit and Compliance - The independent auditor's report on the company's consolidated financial statements is included in the annual report[198]. - The audit committee, comprising three independent non-executive directors, monitors and reviews financial statements and the relationship with external auditors[192]. - The audit committee held two meetings during the reporting period, with full attendance from its members[193]. Community and Environmental Responsibility - The company has established a commitment to environmental protection, adhering to national and local regulations regarding pollution and waste management[80]. - The group made charitable donations totaling RMB 0.3 million during the reporting period[155].
国瑞健康(02329) - 2022 - 年度业绩
2023-04-02 10:08
香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負責,對其準確性或完整性亦不發表任何聲明,並明確表示,概不對因本公告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 GLORY HEALTH INDUSTRY LIMITED 國 瑞 健 康 產 業 有 限 公 司 (於開曼群島註冊成立的有限公司) 2329 (股份代號: ) 截 至 二 零 二 二 年 十 二 月 三 十 一 日 止 年 度 的 年 度 業 績 公 告 財務摘要 - 截至二零二二年十二月三十一日止年度(「報告期」)已簽約銷售額為人 4,531.9 民幣 百萬元; - 受新冠疫情反覆及市場情緒影響,租住市場受壓,本集團自物業開發的 3,340.4 收入為人民幣 百萬元; 7,207,130 - 截至二零二二年十二月三十一日,土地儲備的總建築面積達到 平方米; 55% ...
国瑞健康(02329) - 2022 - 中期财报
2022-09-28 08:55
Sales and Revenue - For the six months ended June 30, 2022, the contracted sales amounted to RMB 2,303.6 million, with a corresponding contracted area of approximately 77,773 square meters[5]. - The revenue for the reporting period was RMB 2,946.27 million, with property development revenue contributing RMB 2,649.55 million[8]. - The average contracted selling price during the reporting period was RMB 29,619.53 per square meter[5]. - The signed sales amount for the first half of 2022 was approximately RMB 2,303.6 million, a decrease of 67.12% compared to RMB 7,007.2 million in the same period of 2021[43]. - Revenue for the six months ended June 30, 2022, was RMB 2,946.27 million, down 55.19% from RMB 6,574.55 million in the same period of 2021[55]. - Property development revenue for the same period was RMB 2,649.55 million, a decrease of 57.10% year-on-year due to reduced delivery area and sales[55]. - The group reported total revenue of RMB 2,946,268 thousand for the six months ended June 30, 2022, compared to RMB 6,574,553 thousand for the same period in 2021, indicating a decline of approximately 55.3%[143][150]. - The property development segment generated revenue of RMB 2,649,546 thousand, while the investment property segment contributed RMB 229,225 thousand during the same period[143][150]. Financial Performance - The company reported a net loss of RMB 777.82 million for the six months ended June 30, 2022[8]. - The group reported a gross loss of RMB 176.32 million and a net loss of RMB 777.82 million for the same period[41]. - The group incurred a segment loss of RMB (390,350) thousand for the six months ended June 30, 2022, compared to a profit of RMB 815,721 thousand for the same period in 2021[152]. - The group reported a pre-tax loss of RMB (854,725) thousand for the six months ended June 30, 2022, compared to a profit of RMB 824,675 thousand for the same period in 2021[152]. - The company reported a loss attributable to shareholders of RMB 682,484,000 for the six months ended June 30, 2022, compared to a profit of RMB 266,546,000 in the same period of 2021[167]. - The basic and diluted loss per share for the period was RMB (15.4), compared to earnings of RMB 6.0 per share in the previous year[117]. Market Conditions - The overall real estate market faced a downturn, with national commodity housing sales area decreasing by 22.2% and sales amount dropping by 28.9% year-on-year[9]. - Fixed asset investment in the country grew by 6.1%, while real estate development investment declined by 5.4%[9]. - The supply of residential land in 300 cities decreased significantly, with supply down 44.3% and transaction volume down 55.6% year-on-year[14]. - The average price of new residential properties in 100 cities increased only by 0.04% month-on-month, indicating price stagnation[15]. Assets and Liabilities - As of June 30, 2022, the total land reserve area reached 7,560,071 square meters[5]. - The company's total borrowings as of June 30, 2022, were RMB 20,686.55 million, with a net debt-to-equity ratio of approximately 136%, up from 130% as of December 31, 2021[71]. - Total assets as of June 30, 2022, were RMB 31,792,535 thousand, a decrease from RMB 35,139,940 thousand as of December 31, 2021[119]. - The company’s total liabilities decreased to RMB 17,995,216 thousand from RMB 16,002,322 thousand[121]. - The company reported a significant increase in receivables, with accounts receivable and other receivables totaling RMB 2,337,938 thousand, up from RMB 1,926,918 thousand[119]. Cost Management - The cost of sales and services for the first half of 2022 was RMB 3,122.59 million, a decrease of 43.50% compared to the previous year[56]. - The group has implemented cost control measures to manage selling and administrative expenses[141]. - Distribution and selling expenses decreased by 33.09% from RMB 100.20 million for the six months ended June 30, 2021, to RMB 67.04 million for the same period in 2022[62]. - Administrative expenses decreased by 12.68% from RMB 190.15 million for the six months ended June 30, 2021, to RMB 166.04 million for the same period in 2022[63]. Corporate Governance - The company has adopted the corporate governance code as per the listing rules, ensuring high levels of transparency and accountability[94]. - The company has established an audit committee consisting of three independent non-executive directors to review accounting principles and internal controls, ensuring compliance with applicable laws and regulations[114]. - The company has implemented an internal control committee that reports quarterly to the board to address regulatory and compliance matters[115]. Future Plans and Strategies - The group plans to accelerate its transformation into the health industry, focusing on hospital, regenerative medicine, and health care projects, which are expected to create greater revenue and profit[36]. - The group aims to optimize its debt structure further to ensure stable development amid ongoing regulatory scrutiny in real estate financing[33]. - The group plans to sell part of its investment properties to improve financial conditions and cash flow[141]. - The group is in discussions with banks to renegotiate loans maturing before June 30, 2023, to ensure continued operations[141]. Shareholder Information - The board has decided not to declare an interim dividend to shareholders[80]. - As of June 30, 2022, the chairman Zhang Zhangsun holds a controlled corporation interest of 3,409,431,570 shares, representing approximately 76.71% of the company's equity[83][84][91]. - The spouse of the executive director, Nguyen Van Juan, also holds an interest in 3,409,431,570 shares, equating to approximately 76.71% of the company's equity[83][91].
国瑞健康(02329) - 2021 - 年度财报
2022-04-28 11:06
年 報 Annual Report 2021 年 Annual Re ( 於開曼群島以「Glory Land Company Limited ( 國瑞置業有限公司 )」的名稱註冊成立的 有限公司 , 並以「Guorui Properties Limited」的名稱在香港經營業務 ) (Incorporated in the Cayman Islands with limited liability under the name of "Glory Land Company Limited (國瑞置業有限公司)" and carrying on business in Hong Kong as "Guorui Properties Limited") 香港聯合交易所股份代號 Stock Code : 2329 目錄 | --- | --- | |-------|--------------------------| | | | | 2 | 財務及營運摘要 | | 3 | 主席報告 | | 6 | 管理層討論及分析 | | 15 | 董事及高級管理層履歷 | | 19 | 董事會報告 | | 34 | 企業管治報 ...
国瑞健康(02329) - 2021 - 中期财报
2021-09-16 09:47
Financial Performance - Revenue for the reporting period was RMB 6,574.6 million, with property development revenue contributing RMB 6,176.7 million[12]. - Gross profit for the reporting period was RMB 1,047.9 million, and net profit was RMB 370.6 million[12]. - The group signed a total contracted sales amount of approximately RMB 7,007.2 million in the first half of 2021, representing a year-on-year increase of 10%[30]. - For the six months ended June 30, 2021, the group's revenue was RMB 6,574.6 million, an increase of 97.9% compared to RMB 3,322.4 million for the same period in 2020[73]. - Property development revenue for the same period was RMB 6,176.7 million, up 111.9% year-on-year, primarily due to increased delivery area from concentrated project completions[73]. - The group's gross profit for the six months ended June 30, 2021, was RMB 1,047.9 million, a 20.3% increase from the previous year, attributed to higher property delivery revenue[75]. - The net profit attributable to the company's owners for the same period was RMB 266.5 million, a significant increase of 273.8% from RMB 71.3 million in the prior year[78]. - Basic and diluted earnings per share for the period were RMB 6.0, compared to RMB 1.6 in the previous year, marking a substantial increase of 275%[151]. Sales and Market Performance - The contracted sales amount for the six months ended June 30, 2021, was RMB 7,007.2 million, with a contracted area of approximately 338,249 square meters[8]. - The average selling price during the reporting period was RMB 20,716 per square meter, with land reserve average cost accounting for 19.8% of the average selling price[8]. - The sales performance in key cities showed significant contributions: Beijing, Xi'an, and Foshan accounted for 59.6%, 10.8%, and 10.1% of total contracted sales, respectively[17]. - The group’s sales performance is expected to remain resilient in core cities due to long-term housing demand supported by economic development and population inflow[18]. Land Reserves and Development - As of June 30, 2021, total land reserves reached 8,545,084 square meters, with an average cost of RMB 4,097.67 per square meter[8]. - The group has 3,528,766 square meters of properties under development and 3,922,326 square meters planned for future development[35]. - The total land reserve amounts to 8,545,084 square meters, with residential properties accounting for 62.2% of the total[64]. - The company has a total of 1,093,992 square meters of land under development, with 3,528,766 square meters planned for future development[67]. Rental Income and Investment Properties - The group's total rental income for the reporting period was RMB 254.9 million, with a projected steady growth in rental income over the next 2 to 5 years due to ownership of 9 investment properties in key cities[19]. - The total area of completed projects as of June 30, 2021, was 1,015,405 square meters, with 75,719 square meters sold, representing a sales rate of approximately 7.5%[58]. - The total leasable area of investment properties was 769,379 square meters, with actual leased area reaching 446,039 square meters, which is 58% of the total[56]. - The company is focusing on expanding its investment properties and enhancing rental income through strategic management and development of existing assets[60]. Financial Health and Cash Flow - The cash, restricted bank deposits, and bank balances as of June 30, 2021, amounted to approximately RMB 2,218.3 million, an increase from RMB 1,896.1 million as of December 31, 2020[23]. - The net debt-to-equity ratio as of June 30, 2021, was approximately 129%, down from 143% at the end of 2020[90]. - The company's total liabilities decreased to RMB 30,276,216 thousand from RMB 34,112,494 thousand, reflecting a reduction of approximately 11.3%[156]. - Net cash generated from operating activities for the six months ended June 30, 2021, was RMB 2,487,872, an increase of 36% compared to RMB 1,832,493 for the same period in 2020[182]. Strategic Initiatives - The company aims to balance sales, investment, and financing to promote high-quality development amid strict regulatory policies[17]. - The company is adapting its product structure to meet diverse market demands and enhance market share[17]. - The group plans to enhance its sales policies and improve product quality to attract more customers and boost sales[24]. - The company plans to continue investing in property development projects and acquiring suitable land in selected cities, with internal resources and bank loans expected to meet funding needs[100]. Corporate Governance and Compliance - The review report from the independent auditor did not contain any reservations or matters requiring emphasis[8]. - The audit committee, consisting of three independent non-executive directors, has reviewed the interim results and confirmed compliance with applicable accounting principles and regulations[140]. - The company has established an internal control committee that reports quarterly to the board to review regulatory, compliance, and internal control matters[141].
国瑞健康(02329) - 2020 - 年度财报
2021-04-29 09:25
GLORY国I瑞 GUORUI PROPERTIES LIMITED 國瑞置業有限公司 〔於開曼群島以「Glory Land Company Limited(日瑞置业有限公司 )」的名稱註冊成立的 有限公司 , 並以「Guorui Properties Limited」的名義在香港経營業務 ) (Incorporated in the Cayman Islands with Ilmited Tablity under the name of "Glory Land Company Limited ( 田瑞置业有限公司)" and carrying on business in Hong Kong as "Guorui Properties Limited") 香港聯合交易所股份代號 Stock Code : 2329 Annual Report 2020 | --- | --- | --- | --- | --- | --- | --- | --- | --- | |-------|-------|---------------------------------|-------|----------|--- ...
国瑞健康(02329) - 2020 - 中期财报
2020-09-16 09:25
Financial Performance - Revenue for the reporting period was RMB 3,322.4 million, with property development revenue accounting for RMB 2,915.4 million[10]. - Gross profit for the reporting period was RMB 871.4 million, with property development gross profit contributing RMB 605.0 million[6]. - Net profit for the reporting period was RMB 281.0 million, resulting in a basic earnings per share of RMB 1.6 cents[6]. - The group's revenue for the six months ended June 30, 2020, was RMB 3,322.4 million, a decrease of 12.0% compared to RMB 3,774.9 million for the same period in 2019[59]. - Property development revenue for the same period was RMB 2,915.4 million, down 14.5% year-on-year, primarily due to uneven completion and delivery[59]. - Gross profit for the six months ended June 30, 2020, was RMB 871.4 million, a decrease of 18.9%, with property development gross profit at RMB 605.0 million, down 24.8%[61]. - The net profit attributable to owners for the six months ended June 30, 2020, was RMB 71.3 million, a significant decrease of 83.4% from RMB 428.6 million in the same period of 2019[63]. - The company reported a basic and diluted earnings per share of RMB 1.6 for the six months ended June 30, 2020, down from RMB 9.6 in 2019[135]. Sales and Market Performance - The contracted sales amount for the six months ended June 30, 2020, was RMB 7,478.8 million, with a corresponding contracted gross floor area of approximately 375,746 square meters[6]. - The contracted sales amount for the first half of 2020 was approximately RMB 7,478.8 million, a decrease from RMB 12,828.3 million in the first half of 2019[28]. - The total contracted sales area for the first half of 2020 was approximately 375,746 square meters, compared to 604,636 square meters in the first half of 2019[28]. - Major contributions to sales came from Beijing (RMB 4,057.8 million, 54.3%), Foshan (RMB 865.5 million, 11.6%), and Suzhou (RMB 556.5 million, 7.4%)[14]. - The real estate market showed signs of recovery, with both sales volume and prices increasing, despite the impact of the COVID-19 pandemic[11]. - The company plans to maintain a proactive sales strategy in the second half of the year, leveraging pent-up demand in the market[11]. Land and Development - The total gross floor area of land reserves reached 15,028,093 square meters, with an average cost of land reserves at RMB 2,890.0 per square meter[6]. - The group has actively undertaken first-level land development projects, with a development area of 5.8 million square meters, of which Shenzhen accounted for 51.6%[18]. - The company is actively pursuing new land acquisitions to support future growth and expansion strategies[39]. - The total land reserve area is 15,028,093 square meters, with 68.5% allocated for residential properties[51]. - The company has 1,112,176 square meters of land under development and 7,011,072 square meters planned for future development[51]. Rental Income and Properties - The total rental income for the group was RMB 278.8 million, with expectations for steady growth in rental income over the next 2 to 5 years due to properties in key cities[16]. - Total rental income for the six months ended June 30, 2020, was RMB 278,817,000, a decrease from RMB 285,120,000 in the same period of 2019, representing a decline of approximately 2.3%[41]. - The total leasable area as of June 30, 2020, was 507,295 square meters, with an actual leased area of 327,977 square meters, indicating a leasing rate of approximately 64.6%[41]. - The company has 983,960 square meters of investment properties in strategic locations, including Beijing and Shenzhen, aimed at generating stable income[32]. - The company selectively retains ownership of most self-developed commercial properties for ongoing revenue generation[32]. Financial Position and Liabilities - Cash, restricted bank deposits, and bank balances amounted to approximately RMB 2,953.9 million, an increase of 33.3% from RMB 2,216.2 million as of December 31, 2019[21]. - The group reduced its interest-bearing liabilities due within one year by 10.4% compared to December 31, 2019[21]. - As of June 30, 2020, the net debt-to-equity ratio was approximately 132%, down from 135% as of December 31, 2019[75]. - The outstanding borrowings amounted to RMB 27,634.1 million, including bank loans of RMB 19,129.1 million and other borrowings of RMB 3,945.4 million[76]. - The company incurred financing costs of RMB 220,466 thousand, an increase from RMB 201,971 thousand in the previous year[132]. Corporate Governance and Shareholder Information - The company maintains a high level of corporate governance, adhering to the corporate governance code as per the listing rules[105]. - The company emphasizes shareholder transparency and accountability as part of its governance practices[105]. - The company has implemented a share incentive plan, awarding a total of 33,617,700 shares to selected individuals[110]. - The company has disclosed the interests of its directors and major shareholders, ensuring compliance with securities and futures regulations[102]. - The board decided not to declare an interim dividend for shareholders[88].
国瑞健康(02329) - 2019 - 年度财报
2020-05-14 08:44
GLORY国I洲 GUORUI PROPERTIES LIMITED 國瑞置業有限公司 2019 年報 Annual Report ( 於開曼群島以「Glory Land Company Limited(国瑞置业有限公司 }」的名稱註冊成立的 有限公司 , 並以「Guorui Properties Limited J 的名稱在香港經營業務 ) (Incorporated in the Cayman Islands with Imited liability under the name of "Glory Land Company Limited (田瑞置业有限公司)" and carrying on business in Hong Kong as "Guorul Properties Limited") 香港聯合交易所股份代號 Stock Code : 2329 2 209 3 主席報告 210 7 214 230 235 董事會報告 251 58 公司資料 265 59 267 64 272 66 綜合財務狀況表 綜合權益變動表 279 財務及營運摘要 管理層討論及分析 23 董事及高級管理層履歷 28 ...
国瑞健康(02329) - 2019 - 中期财报
2019-09-12 09:10
GLORY国瑞 GUORUI PROPERTIES LIMITED 國瑞置業有限公司 中 期 報 告 Interim Report 2019 ( 於開曼群島以「Glory Land Company Limited(国瑞置业有限公司)」的名稱註冊成立的 有限公司,並以「Gucrui Properties Limited」的名稱在香港經營業務 ) (Incorporated in the Cayman Islands with Imited Tablity under the name of "Glory Land Company Limited (田瑞置业有限公司)" and carrying on business in Hong Kong as "Guorui Properties Limited") 香港聯合交易所股份代號 Stock Code : 2329 目錄 CONTENTS 1 公司資料 2 財務摘要 3 主席報告 7 管理層討論及分析 23 權益披露 25 企業管治常規及其他資料 30 簡明綜合財務報表的審閱報告 31 簡明綜合損益及其他綜合收益表 33 簡明綜合財務狀況表 35 簡明綜合權益變 ...